Herein, we presented the effectiveness of the novel, highly specific Syk inhibitor TAK-659 in suppressing the induction of survival, proliferation and migration of CLL cells by the microenvironment, thus providing the biological rationale for its clinical development in CLL. The gene discussed is SYK; the disease is B-cell chronic lymphocytic leukemia.